Parasitic Diseases Therapeutics

Global Parasitic Diseases Therapeutics Market to Reach US$2.2 Billion by 2030

The global market for Parasitic Diseases Therapeutics estimated at US$1.8 Billion in the year 2024, is expected to reach US$2.2 Billion by 2030, growing at a CAGR of 3.2% over the analysis period 2024-2030. Anthelmintics Drugs, one of the segments analyzed in the report, is expected to record a 3.4% CAGR and reach US$1.1 Billion by the end of the analysis period. Growth in the Antiprotozoals Drugs segment is estimated at 2.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$486.4 Million While China is Forecast to Grow at 6.3% CAGR

The Parasitic Diseases Therapeutics market in the U.S. is estimated at US$486.4 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$449.5 Million by the year 2030 trailing a CAGR of 6.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.0% and 2.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Global Parasitic Diseases Therapeutics Market - Key Trends and Drivers Summarized

Parasitic diseases, caused by various organisms such as protozoa, helminths, and ectoparasites, continue to pose significant public health challenges worldwide, particularly in tropical and subtropical regions. These diseases, including malaria, leishmaniasis, schistosomiasis, and lymphatic filariasis, often result in severe morbidity and mortality, particularly among children and immunocompromised individuals. Therapeutics for parasitic diseases involve a range of treatments designed to eliminate the parasites from the host body, alleviate symptoms, and prevent transmission. Traditional treatments have included antiparasitic drugs such as chloroquine for malaria and albendazole for helminth infections, which have been the mainstay of treatment for decades. However, the emergence of drug-resistant strains of parasites has necessitated the development of new and more effective therapeutics to combat these diseases.

Recent advancements in the field of parasitic disease therapeutics have been driven by innovative research and development efforts focusing on novel drug discovery, vaccine development, and combination therapies. Researchers are employing high-throughput screening techniques to identify new drug candidates, leveraging advances in genomics and proteomics to understand parasite biology better and discover new drug targets. The development of vaccines against parasitic diseases, such as the RTS,S/AS01 malaria vaccine, represents a significant breakthrough in preventing infection and reducing disease burden. Additionally, combination therapies, which use multiple drugs with different mechanisms of action, are being increasingly utilized to enhance treatment efficacy and delay the onset of drug resistance. This multifaceted approach is crucial in managing parasitic diseases, given the complex life cycles of parasites and their ability to adapt and survive under various conditions.

The growth in the parasitic diseases therapeutics market is driven by several factors, including the increasing prevalence of parasitic infections due to global travel, climate change, and inadequate sanitation in developing regions. Technological advancements in diagnostic tools have improved the early detection and accurate diagnosis of parasitic diseases, facilitating timely and effective treatment. Consumer behavior, particularly in regions with high disease prevalence, shows a growing demand for accessible and affordable treatments. Additionally, global health initiatives and funding from organizations such as the World Health Organization (WHO) and the Bill & Melinda Gates Foundation have provided substantial support for research and development in this field. Regulatory incentives and fast-track approvals for new antiparasitic drugs and vaccines also contribute to market growth. As pharmaceutical companies continue to invest in innovative treatments and expand their reach into emerging markets, the parasitic diseases therapeutics market is expected to grow, offering improved health outcomes and enhanced quality of life for affected populations.

SCOPE OF STUDY:

The report analyzes the Parasitic Diseases Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Drug Type (Anthelmintics Drugs, Antiprotozoals Drugs, Other Drug Types); Distribution Channel (Hospital Pharmacies , Retail Pharmacies, Other Distribution Channel Pharmacies)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• Amneal Pharmaceuticals LLC
• Bayer AG
• Cipla Ltd
• GSK Plc
• Johnson & Johnson Services, Inc.
• Merck KGaA
• Novartis AG
• Pfizer, Inc.
• Reese Pharmaceutical Company
• Sanaria Inc.
• Sanofi SA
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceuticals USA, Inc.
• Victor Medical Company
• Zydus Pharmaceuticals (USA) Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.